Abstract: Bevacizumab is the first drug in the world aimed at angiogenesis.Since gaining FDA approval in 2004, this drug has attracted much attention.In combination with standard chemotherapy, bevacizumab has a definitive effect on several solid tumors, such as colorectal cancer, non-small cell lung cancer, and renal cell cancer.Bevacizumab significantly prolongs and improves the quality of a patient's life.Despite the number of related studies, scientists have not yet identified who benefits the most from bevacizumab.This article reviews the accomplishments and questions of recent studies concerning the predictive factors of bevacizumab.